Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a veterans affairs population

International Clinical Psychopharmacology

Volumn 24, Issue 4, 2009, Pages 204-213

  Duncan, Erica J ^a,b   Woolson, Sandra L ^c   Hamer, Robert M ^c,d   Dunlop, Boadie W ^b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d IL   (United States)

Author keywords

Antipsychotic agents; Haloperidol; Lipids; Olanzapine; Quetiapine; Risperidone

Indexed keywords

CHOLESTEROL; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; ANXIETY DISORDER; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; DIBENZOTHIAZEPINES; DYSLIPIDEMIAS; FEMALE; HALOPERIDOL; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISPERIDONE; TIME FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 67651216043     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32832d6c18     Document Type: Article

References (24)

1. Bouchard RH, Demers M-F, Simoneau I, Almeras N, Villeneuve J, Mottard J-P, et al. (2001). Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin Psychopharmacol 21:110-111.
2. Brown WV, Jacobson TA (2000). The management of lipoprotein disorders. In: Branch WT, Alexander RW, Schlant RC, Hurst JW, editors. Cardiology in primary care. New York: MacGraw-Hill Companies. pp. 201-222.
3. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. (2000). Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903-912.
4. Duncan E, Dunlop BW, Boshoven W, Woolson SL, Hamer RM, Phillips LS (2007). Relative risk of glucose elevation during antipsychotic exposure in a veterans administration population. Int Clin Psychopharmacol 22:1-11.
5. Dunlop BW, Sternberg M, Phillips LS, Andersen J, Duncan E (2003). Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. Psychopharmacol Bull 37:99-117.
6. Eberly LE, Stamler J, Neaton JD; Multiple Risk Factor Intervention Trial Research Group (2003). Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 163:1077-1083.
7. Expert Committee (2003). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26:S5-S20.
8. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ (2005). Metabolic syndrome in bipolar disorder: findings from the bipolar disorder center for Pennsylvanians. Bipolar Disord 7:424-430.
9. Hardy TA, Marquez E, Kryzhanovskaya L, Taylor CC, Cavazzoni P (2006). Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. J Clin Psychopharmacol 26:405-408.
10. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J (2003). Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64:575-579.
11. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. (2000). Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975-981.
12. Huang TL, Chen JF (2005). Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res 80:55-59.
13. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, et al. (2002). An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 59:1021-1026.
14. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med 353:1209-1223.
15. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. (2004). A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65 (Suppl 18):47-56.
16. Meyer J, Koro CE, L'Italien GJ (2005). The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry 17:173-180.
17. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86:15-22.
18. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl 1): 1-93.
19. Newcomer JW (2007). Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68 (Suppl 1): 20-27.
20. Newcomer JW, Haupt DW (2006). The metabolic effects of antipsychotic medications. Can J Psychiatry 51:480-491.
21. Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000). Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45:21-28.
22. Rettenbacher MA, Ebenbichler C, Hofer A, Kemmler G, Baumgartner S, Edlinger M, et al. (2006). Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol 21:369-372.
23. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al. (2007). Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 164:415-427.
24. Wu RR, Zhao JP, Zhai JG, Guo XF, Guo WB (2007). Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostatic and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol 27:374-379.